NEW EVENT! Cutting-edge Trends for Life Sciences at PACK EXPO Southeast
Discover all the latest packaging solutions for life sciences products at the all-new PACK EXPO Southeast in Atlanta, GA, March 10-12, 2025

Novartis Enters EpiPen Game With Adamis Deal

Novartis’ Sandoz unit acquires U.S. rights to Symjepi, the prefilled epinephrine syringe from Adamis Pharmaceuticals.

Novartis
Novartis

Lack of competition and flubbed roll-outs of EpiPen alternatives has left the market wide open, allowing Mylan to make aggressive price hikes on its sweetheart blockbuster. However, a recent FiercePharma article noted an acquisition play by Swiss drugmaker Novartis that could level the playing field.

Novartis’ generics department, Sandoz, inked a deal with Adamis to market their EpiPen alternative, Symjepi. While the name might not be as catchy as the original, the pre-filled epinephrine syringes have a chance to become a major player in the EpiPen market with Novartis’ marketing muscle behind it. No financial details of the deal have been released, but allegedly Adamis will receive a large upfront payment plus half of net profits.

The FDA approved Symjepi last June, and it took the company a full year to find a marketing partner, but it seems now is the time for the product to roll out. The company has not yet disclosed the price of its product, but a spokesperson noted, “We want to position this product as a low-cost alternative to the other current offerings in the anaphylaxis market.”

INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast
The exciting new PACK EXPO Southeast 2025 unites all vertical markets in one dynamic hub, generating more innovative answers to packaging challenges for life sciences products. Don’t miss this extraordinary opportunity for your business!
REGISTER FOR $30!
INTRODUCING! The Latest Trends for Life Sciences at PACK EXPO Southeast